Evidence map›Paper›PMID 42164587›Full record

ArticleJournal of intensive medicine2026

Efficacy and safety of remimazolam besylate in patients receiving mechanical ventilation: A randomized phase Ⅱa trial.

Xiaobo Yang, Shouzhi Fu, Li Yu, Fengming Liang, Dezhong Li, Renhua Sun, Xiang Zhou, Xinting Yu, Luanyuan Tian, You Shang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of intensive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaobo YangDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Shouzhi FuDepartment of Critical Care Medicine, Wuhan Third Hospital, Wuhan, Hubei, China.
Li YuDepartment of Critical Care Medicine, The Central Hospital of Wuhan, Wuhan, Hubei, China.
Fengming LiangDepartment of Critical Care Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Dezhong LiDepartment of Critical Care Medicine, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, Hubei, China.
Renhua SunDepartment of Critical Care Medicine, Peolple's Hospital of Zhejiang, Hangzhou, Zhejiang, China.
Xiang ZhouYichang Humanwell Pharmaceutical Co., Ltd, Yichang, Hubei, China.
Xinting YuYichang Humanwell Pharmaceutical Co., Ltd, Yichang, Hubei, China.
Luanyuan TianYichang Humanwell Pharmaceutical Co., Ltd, Yichang, Hubei, China.
You ShangDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To preliminarily evaluate the efficacy, safety and continuous infusion dose of remimazolam besylate in short-term mechanically ventilated patients in intensive care units. Methods: This randomized phase Ⅱa trial was conducted in intensive care units (ICUs) in six hospitals in China. Adults that were anticipated to receive mechanical ventilation for ≥6 h and to have a Richmond Agitation-Sedation Scale (RASS) scores of -2 to +1 were enrolled in the trial and randomized (1:1:1) into three groups to receive 0.1, 0.2, or 0.4 mg/(kg·h) remimazolam besylate. The primary outcome was the percentage of time with the target RASS scores without rescue sedation. The secondary outcome was adverse drug reactions (ADRs). The optimal continuous infusion dose was also explored. Results: The percentage of time with the target RASS scores without rescue sedation did not differ among the groups (97.5±6.0 in the 0.1 mg/(kg·h) group with 11 participants, 95.2±8.0 in the 0.2 mg/(kg·h) group with 12 participants, and 97.0±2.4 in the 0.4 mg/(kg·h) group with 11 participants; Conclusions: Remimazolam besylate seems efficacious and safe in patients receiving short-term mechanical ventilation and light sedation, which justifies further trials.

Indexed as

Adverse drug reactionEfficacyMechanical ventilationRemimazolam besylateRichmond Agitation-Sedation ScaleSafety

Identifiers

PMID42164587
PMCPMC13184453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.